A new publication involving the peptide LL-37 appeared on September 16, 2026. The paper, titled "Cathelicidin LL-37 inhibits angiogenesis and migration in gastric cancer via inhibition of NF-κB/IL-6 signaling," was published in the journal Histology and Histopathology.
LL-37 remains classified as an unapproved compound intended for research use. This publication is listed under PubMed ID 42745581 and is indexed as a new addition to the scientific literature on this peptide.
The title indicates the study's focus on angiogenesis and migration processes in gastric cancer, and the role of NF-κB/IL-6 signaling in this context. No specific findings, data, or conclusions beyond the title have been disclosed in this brief, as only the publication record itself is being reported at this time.
Readers interested in the broader context of LL-37 research, including its classification and other studies, can consult the compound overview for additional background information.